Methylphenidate Actavis (Methylphenidate Hydrochloride)

Methylphenidate Actavis is a central nervous system stimulant indicated for disorders involving attention regulation and excessive daytime sleepiness.

• Attention deficit hyperactivity disorder (ADHD) in children and adolescents: improves concentration, reduces hyperactivity and impulsivity, supporting better academic and social performance.
• Attention deficit hyperactivity disorder (ADHD) in adults: enhances focus and reduces distractibility, aiding occupational and daily functioning.
• Narcolepsy: decreases daytime sleepiness and cataplexy episodes, helping patients maintain wakefulness and functional daily activities.

• Methylphenidate inhibits the reuptake of dopamine and norepinephrine by blocking their respective transporters in neuronal synapses. This increases the extracellular concentrations of these catecholamines, enhancing neurotransmission in brain regions that regulate attention, impulse control, and wakefulness.

Adverse reactions may occur with methylphenidate therapy and vary in frequency and severity.

Common Side Effects

• Insomnia: difficulty initiating or maintaining sleep.
• Appetite loss: reduced desire to eat, potentially leading to weight loss.
• Headache: mild to moderate tension‑type pain.
• Dry mouth: sensation of oral dryness.
• Increased heart rate: mild tachycardia.
• Nervousness: feelings of anxiety or jitteriness.

Serious or Rare Side Effects

• Cardiovascular events: chest pain, hypertension, or arrhythmias.
• Psychiatric symptoms: new or worsening psychosis, mania, or severe anxiety.
• Growth suppression: reduced height velocity in children.
• Peripheral vasculitis: inflammation of small blood vessels.
• Allergic reactions: rash, urticaria, or anaphylaxis.
• Seizures: rare occurrence of convulsive episodes.

Before initiating methylphenidate, clinicians should evaluate patient history and monitor for specific risks.

• Cardiovascular assessment: check blood pressure and heart rate, and review cardiac history.
• Psychiatric evaluation: assess for pre‑existing psychosis, bipolar disorder, or severe anxiety.
• Growth monitoring: regularly measure height and weight in pediatric patients.
• Substance misuse screening: consider risk of abuse or dependence.
• Drug‑specific contraindications: avoid use in patients with known hypersensitivity to methylphenidate.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Methylphenidate may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis.
• Sympathomimetic agents (e.g., pseudoephedrine): may cause severe hypertension or tachyarrhythmia.
• Antipsychotics (e.g., haloperidol): can reduce methylphenidate effectiveness.

Moderate Interactions (Monitor Closely):\n- Antihypertensives: possible attenuation of blood‑pressure‑lowering effect.

• CYP2D6 inhibitors (e.g., fluoxetine): may increase methylphenidate plasma levels.
• Acid‑reducing agents (e.g., omeprazole): may affect absorption modestly.